BioCentury
ARTICLE | Clinical News

Toraymyxin: Completed Phase III enrollment

June 27, 2016 7:00 AM UTC

Spectral completed enrollment of 446 patients in the double-blind, sham-controlled, North American Phase III EUPHRATES trial comparing Toraymyxin plus standard of care (SOC) vs. SOC alone. ...